Tech Transfer Central
Tech Transfer eNews

Tech Transfer E-News provides a weekly round-up of current news and information in the world of tech transfer, delivered every Wednesday (sign up here). It is published by Technology Transfer Tactics newsletter, which is available as a monthly subscription. For more information or to order a subscription click here, or for a sample issue, click here.

Hebrew University researchers create injectable antibiotic to lower pandemic morbidity rates

Hebrew University researchers have developed an injectable antibiotic that could significantly reduce the morbidity rate for pandemics such as COVID-19.

The research team reformulated Mupirocin, a highly effective topical antibiotic, to allow for intravenous delivery, in the process creating new properties to fight drug-resistant bacteria. According to some studies, nearly 50% of COVID-19 deaths involved secondary bacterial infections.

“The ability to take an existing drug and alter the way it works can have a significant impact on the problem of antibiotic resistance and secondary bacterial infections related to COVID-19 and may pave the way for a new treatment regimen,” says Yechezkel Barenholz, head of the Hebrew University research team. “We have had very strong results from relevant animal models, and are looking forward to moving into clinical trials with Nano-mupirocin (the nano-liposomal formulation of mupirocin), as we believe the potential of this discovery is immense.”

The researchers have received support from the National Institutes of Health (NIH) for the treatment, which was part of a groundbreaking study conducted with their German collagues at Helmholtz for Infection Research (HZI).

“Our study demonstrates how nano-liposomes have enabled the creation of a novel injectable antibiotic, and how we have overcome the limitations of existing antibiotics by using nano-technology approaches,” says Ahuva Cern, a co-researcher on the project. “This drug, if approved, fundamentally enhances the arsenal of antibiotics available to treat resistant infections, including those associated with COVID-19.” Source:

Posted under: Tech Transfer e-News